Compare · NPCE vs SYK
NPCE vs SYK
Side-by-side comparison of Neuropace Inc. (NPCE) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NPCE and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $126.81B, about 260.9x NPCE ($486.0M).
- SYK has been more active in the news (9 items in the past 4 weeks vs 4 for NPCE).
- SYK has more recent analyst coverage (25 ratings vs 16 for NPCE).
- Company
- Neuropace Inc.
- Stryker Corporation
- Price
- -
- -
- Market cap
- $486.0M
- $126.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 4
- 9
- Recent ratings
- 16
- 25
Neuropace Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest NPCE
- Amendment: SEC Form SCHEDULE 13G/A filed by Neuropace Inc.
- SEC Form 10-Q filed by Neuropace Inc.
- Neuropace Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
- Neuropace Inc. filed SEC Form 8-K: Regulation FD Disclosure
- NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
- Mizuho initiated coverage on NeuroPace with a new price target
- CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 335 shares, decreasing direct ownership by 0.64% to 52,050 units (SEC Form 4) to satisfy withholding obligation
- Director Geiger Uri was granted 789 shares, increasing direct ownership by 4% to 18,537 units (SEC Form 4)
- Director Fischer Frank M was granted 1,467 shares, increasing direct ownership by 0.25% to 599,534 units (SEC Form 4)
Latest SYK
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- Stryker declares an $0.88 per share quarterly dividend
- VP, Chief Comm. Officer Montagnino Kimberly Ann covered exercise/tax liability with 155 shares, decreasing direct ownership by 8% to 1,717 units (SEC Form 4)
- Officer King Debra covered exercise/tax liability with 533 shares, decreasing direct ownership by 7% to 7,036 units (SEC Form 4)
- VP, Chief Legal Officer Fletcher Robert S covered exercise/tax liability with 94 shares, decreasing direct ownership by 0.89% to 10,488 units (SEC Form 4)
- VP, Chief HR Officer Fink M Kathryn covered exercise/tax liability with 111 shares, decreasing direct ownership by 0.84% to 13,027 units (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation